Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a “real world” study

Author:

Epperla Narendranath1,Hamadani Mehdi1,Cashen Amanda F.2,Ahn Kwang W.1,Oak Eunhye2,Kanate Abraham S.3,Calzada Oscar4,Cohen Jonathon B.4,Farmer Luke5,Ghosh Nilanjan5,Tallarico Michael6,Nabhan Chadi6,Costa Luciano J.7,Kenkre Vaishalee P.8,Hari Parameswaran N.1,Fenske Timothy S.1

Affiliation:

1. Division of Hematology and Oncology; Medical College of Wisconsin; Milwaukee WI USA

2. Division of Medical Oncology; Washington University School of Medicine; St. Louis MO USA

3. Division of Hematology and Oncology; West Virginia University; Morgantown WV USA

4. Department of Hematology and Medical Oncology, Winship Cancer Institute; Emory University; Atlanta GA USA

5. Department of Hematology and Oncology; Levine Cancer Institute/Carolinas HealthCare System; Charlotte NC USA

6. Division of Hematology and Oncology; University of Chicago; Chicago IL USA

7. Bone Marrow Transplantation and Cell Therapy Program; University of Alabama; Birmingham AL USA

8. Division of Hematology and Oncology; University of Wisconsin; Madison WI USA

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3